BenevolentAl Therapeutics Pipeline and Triage
BEN-8744 is a highly potent and selective PDE10 inhibitor
Primary Pharmacology¹
Safety Pharmacology'
Human PDE10 IC50 (biochem <InM
HERG IC50
13uM
& cell-based assays)
CaV1.2 IC50
>30uM
Mouse PDE10 IC50
<InM
Nav1.5 Ic50
>30uM
IC50 in IBD biopsy
<InM
inflammatory cytokine
Human iPSC-derived
No flags
release assay (UC & Crohn's)
cardiomyocyte toxicity
Selectivity vs other PDE
≥1000 fold
family members
Selectivity vs broad panel of safety
targets (Cerep87)
≥1000 fold
Highly potent
Good selectivity
No safety flags
Ames (5 strain, +/- S9)
IVMN
Hepatic toxicity (hepatocyte
cytotoxicity; DILI panel, 14 day 3D
liver organoid assay)
7 day rat toxicology study
Negative
Negative
Negative
No overt toxicity or
clinical observations
>100x predicted hAUC
Al
Benevolent 42
1 Company internal drug programme dataView entire presentation